Breakthroughs in immunotherapy and a rush to develop profitable new treatments have brought a crush of clinical trials scrambling for patients.
GINA KOLATA, NY Times: Health
Sat, 08/12/2017 - 11:00am
Breakthroughs in immunotherapy and a rush to develop profitable new treatments have brought a crush of clinical trials scrambling for patients.